ASCO Annual Meeting
Annual Meeting of American Society of Clinical Oncology (ASCO)
Chicago, June 4 - June 6, 2010
Investor Updates
- Roche to Present New Data on Different Approaches To Treating Cancer at ASCO read more
- Phase III study showed first-line maintenance use of MabThera doubles likelihood of people with follicular lymphoma living without their disease worsening read more
- Roche Investor Event: ASCO 2010 read more
- Roche presents early data on the next generation of therapeutic antibodies and other targeted therapies at ASCO read more
- Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening read more
More Information
ASCO coverage for media
Webcast
Analyst briefing on data presented at ASCO: Sunday, June 6
Highlights:
Setting the standard of care in oncology
Pascal Soriot, COO Roche Pharmaceuticals
Avastin in ovarian cancer, GOG-0218 study data
Jakob Dupont, M.D., M.A., Associate Group Medical Director Avastin Global ClinicalDevelopment, Genentech
Overview of Avastin development program
Stefan Frings, M.D., Ph.D., Avastin Franchise Director, Roche
MabThera/Rituxan maintenance in previously untreated patients with follicular lymphoma (PRIMA study)
Gilles Salles, M.D., Ph.D., Principal Investigator of PRIMA study Centre Hospitalier Lyon-Sud, France
Overview of Roche/Genentech oncology pipeline
Hal Barron, M.D., Executive Vice President, Global Development and Chief Medical Officer, Roche